Showing 451-460 of 8075 results for "".
Current and Future Treatments
https://practicaldermatology.com/series/updates-vitiligo/current-and-future-treatments/26622/Dr. Karan Lal, a double board-certified adult and pediatric dermatologist and fellowship-trained cosmetic dermatologist with Affiliated Dermatology in Scottsdale, Arizona, talks with Practical Dermatology about the various options available today for repigmentation and treating flare-ups in vitiligoCombination Therapy for Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/combination-therapy-vitiligo-treatment/26561/Dr. Natasha Atanaskova Mesinkovsa, Vice Chair for Clinical Research at the University of California, Irvine, talks with Practical Dermatology about phototherapy in combination with topical JAK inhibitors for vitiligo. Dr. Mesinkovska also discusses the efficacy of at-home devices and mortality ratesSCALE 2024: Dr. Hilary Baldwin’s Tips and Tricks for Treating Keloids
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwins-tips-and-tricks-for-treating-keloids/26366/Hilary E. Baldwin, MD, discusses best practices for the treatment of keloids at Music City SCALE.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinHow Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedAesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systTeledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolClinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Hormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study